Skip to main content
Fig. 5 | Journal of Neuroinflammation

Fig. 5

From: The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson’s disease

Fig. 5

Effect of CD200 deficiency on MPTP-induced dopaminergic neurodegeneration and microglial activation at day 7 after administration. Mice were injected intraperitoneally with saline or MPTP (18 mg/kg) every 2 h to a total of 4 doses in 1 day. Mice were sacrificed 7 days following the last MPTP injection and brains were fixed for immunohistochemistry. a TH immunostaining in striatum and optical densitometry of striatal TH-positive dopaminergic fibers of saline- and MPTP-treated CD200 +/+ and CD200 −/− mice. b TH immunostaining and stereological cell counts of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of saline- and MPTP-treated CD200 +/+ and CD200 −/− mice. c Representative photomicrographs of IBA1-immunostained substantia nigra (SN) of CD200 +/+ and CD200 −/− mice treated with saline or MPTP. Quantification of the IBA1-labelled area (d) and the immunolabelling intensity of IBA1-positive cells (e) in total SN and SNpc of saline- and MPTP-treated CD200 +/+ and CD200 −/− mice. Bars are means + SEM of five to eight mice per experimental group. *p < 0.05, **p < 0.01 and ***p < 0.001 vs. saline; two-way ANOVA and Bonferroni post hoc test. Scale bars: 500 μm (striatum) and 200 μm (SN and SNpc)

Back to article page
\